Erythro-austrobailignan-6 down-regulates HER2/EGFR/integrinβ3 expression via p38 activation in breast cancer

  • Phytomedicine. 2017 Jan 15;24:24-30. doi: 10.1016/j.phymed.2016.11.009.
Jae-Hyun Han  1 ,  Ha Jin Jeong  2 ,  Han Na Lee  3 ,  Yun Ju Kwon  3 ,  Heung-Mook Shin  3 ,  Yura Choi  4 ,  Seongmi Lee  4 ,  Seung Tack Oh  4 ,  Dong-Il Kim  5 ,  Songhee Jeon  6
Affiliations
  • 1. Department of Obstetrics & Gynecology, Graduate School of Oriental Medicine, Dongguk University, Gyeongju, Republic of Korea.
  • 2. Department of Biomedical Sciences, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju, 61469, Republic of Korea.
  • 3. Natural Product Bank of Korea Promotion Institute for Traditional Medical Industry, 94, Hwarang-ro, Gyeongsan-si, Gyeongsangbuk-do, Republic of Korea.
  • 4. Department of Biomedical Engineering, Dongguk University, Gyeonggi-do 10326, Republic of Korea.
  • 5. Department of Obstetrics & Gynecology, College of Korean Medicine, Dongguk University Ilsan Hospital, 27, Dongguk-ro, Siksa-dong, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Republic of Korea. Electronic address: [email protected].
  • 6. Department of Biomedical Sciences, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju, 61469, Republic of Korea. Electronic address: [email protected].
PMID: 28160858 DOI: 10.1016/j.phymed.2016.11.009
Abstract

Background: Despite the benefits from different options of therapy for breast Cancer, resistance of the disease to these therapies is rising and a novel agent is needed. Erythro-austrobailignan-6 (EA6) exhibits anti-cancer activity. However, the detailed anti-tumor mechanisms by which EA6 inhibits 4T-1 and MCF-7 cell growth have not been well studied.

Purpose: In this study, we investigated the anti-proliferative and anti-tumor properties of EA6 on breast carcinoma and its accompanying mechanisms.

Methods: The cytotoxic and apoptotic effect of EA6 were measured in breast Cancer cell lines of 4T-1 and MCF-7. The role of EA6 on cell proliferation and migration was examined by immunoblotting. The anti-tumor activity of EA6 was assessed in mice inoculated with 4T-1 breast Cancer cells.

Results: EA6 increased the number of Annexin V-positive apoptotic bodies and cleaved form of Caspase-3 in a dose-dependent manner and phosphorylated JNK and p38 in both cells. Moreover, EA6 down-regulated cell cycle dependent proteins of CDK-4 and cyclin D1, and increased G0/G1 population in both cells. EA6-induced Apoptosis is mediated by p38 MAPK and Caspase-3 activation in both cells. EA6 significantly reduced HER2/EGFR/Integrin β3 expression and Src phosphorylation, which was dependent on p38 MAPK activation in 4T-1 and MCF-7 cells. Furthermore, we confirmed the down-regulation of topoisomerases by EA6 treatment, but the overall effects of EA6 on Topoisomerase isotype were cell type specific. Finally, EA6 (20mg/kg/day) significantly reduced mammary tumor volume in 4T-1 bearing mice by down-regulating HER2/EGFR/Integrin β3 expression in tumor tissues.

Conclusions: Our results offer a novel insight into the mechanism of EA6-induced Apoptosis in breast Cancer cells. We propose that EA6 treatment resulted in the activation of p38 MAPK and Caspase-3, which eventually participated in regulating Apoptosis in 4T-1 and MCF-7 cells.

Keywords
Breast cancer; Caspase-3; EGFR; Erythro-austrobailignan-6, p38; Topoisomerase.
Products